HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.69, Iss.1, 2001-09, pp. : 53-63

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients

By Lüftner D.

Breast Cancer Research and Treatment, Vol. 80, Iss. 3, 2003-08 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite

Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma

By Bermont L.

Breast Cancer Research and Treatment, Vol. 63, Iss. 2, 2000-09 ,pp. : 163-169

Springer Publishing Company

Access to resources Recommend Favorite

HER-2/neu Assessment in Primary Chemotherapy Treated Breast Carcinoma: No Evidence of Gene Profile Changing

By Dagrada G.P.

Breast Cancer Research and Treatment, Vol. 80, Iss. 2, 2003-07 ,pp. : 207-214

Springer Publishing Company

Access to resources Recommend Favorite

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer

By Disis M.L. Knutson K.L. Schiffman K. Rinn K. McNeel D.G.

Breast Cancer Research and Treatment, Vol. 62, Iss. 3, 2000-08 ,pp. : 245-252

Springer Publishing Company

Access to resources Recommend Favorite

Bilateral Synchronous Breast Cancer and HER-2/ neu Overexpression

By Safa Malek Lower Elyse Hasselgren P.O. Hungness Eric Gazder Paula Aron Bernard Shaughnessy Elizabeth Yassin Rawia

Breast Cancer Research and Treatment, Vol. 72, Iss. 3, 2002-04 ,pp. : 195-201

Springer Publishing Company

Access to resources Recommend Favorite